Publication Beamlines Strategic Pillar
Boyes, Courtis (2024). Comparative Analysis and Speciation of Sulfur K, L-edge X-ray Absorption Spectroscopy. Supervisor: George, Graham; Pickering, Ingrid. Saskatchewan, Canada: University of Saskatchewan. https://harvest.usask.ca/items/15d42a7c-89f4-4ab2-b51d-253e3c0a858f. BIOXAS-MAIN, VLS-PGM Environment
Boyes, Courtis (2024). Comparative Analysis and Speciation of Sulfur K, L-edge X-ray Absorption Spectroscopy. Supervisor: George, Graham; Pickering, Ingrid. Saskatchewan, Canada: University of Saskatchewan. https://harvest.usask.ca/items/15d42a7c-89f4-4ab2-b51d-253e3c0a858f. BIOXAS-MAIN, VLS-PGM Environment
Rachelle Elizabeth Davenport (2024). How Decomposition affects the molecular diversity of soil organic matter and its persistence. Supervisor: Lehmann, Johannes. New York, United States: Cornell University. . SGM Environment
Philip Adebayo Adene (2024). BIOGEOCHEMICAL IMPLICATIONS OF SULFATE-BASED COAGULANTS IN TREATED OIL SANDS FLUID FINE TAILINGS. Supervisor: Matthew Lindsay. Saskatoon, Canada: University of Saskatchewan. . CMCF, SXRMB Environment
Philip Adebayo Adene (2024). BIOGEOCHEMICAL IMPLICATIONS OF SULFATE-BASED COAGULANTS IN TREATED OIL SANDS FLUID FINE TAILINGS. Supervisor: Matthew Lindsay. Saskatoon, Canada: University of Saskatchewan. . CMCF, SXRMB Environment
Zimmermann, Elizabeth A.; DeVet, Taylor; Cilla, Myriam; Albiol, Laia; Kavaseri, Kyle et al. (2024). Tissue material properties, whole-bone morphology and mechanical behavior in the Fbn1C1041G/+ mouse model of Marfan syndrome. Matrix Biology Plus 23, 100155. 10.1016/j.mbplus.2024.100155. BMIT-BM Health
Zhu, Yuao; Yurgelonis, Irina; Noell, Stephen; Yang, Qingyi; Guan, Shunjie et al. (2024). In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Science Advances 10(30) . 10.1126/sciadv.adl4013. [PDB: 9aum] CMCF-ID Health
Zhou, Yuebiao; Aliagas, Ignacio; Wang, Shumei; Li, Chun Sing; Liu, Zhiguo et al. (2024). Discovery of potent dihydro-oxazinoquinolinone inhibitors of GuaB for the treatment of tuberculosis. Bioorganic and Medicinal Chemistry Letters , 130026. 10.1016/j.bmcl.2024.130026. [PDB: 9dc8, 9dc9] CMCF-BM Health
Zheng, Xiaozhang; Ji, Nan; Campbell, Veronica; Slavin, Anthony; Zhu, Xiao et al. (2024). Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry . 10.1021/acs.jmedchem.4c01305. [PDB: 9cuo] CMCF-ID Health
Ye, Qilu; Eves, Robert; Vance, Tyler D. R.; Hansen, Thomas; Sage, Adam P. et al. (2025). Aeromonas hydrophila RTX adhesin has three ligand-binding domains that give the bacterium the potential to adhere to and aggregate a wide variety of cell types. mBio 16(5) . 10.1128/mbio.03158-24. [PDB: 9cse] CMCF-ID Health
Xu, Shangyi; Grochulski, Pawel; Tanaka, Takuji (2024). Structural basis for the allosteric behaviour and substrate specificity of Lactococcus lactis Prolidase. Biochimica et Biophysica Acta - Proteins and Proteomics 1872(3) , 141000. 10.1016/j.bbapap.2024.141000. CMCF-BM, CMCF-ID Health
Xu, Shangyi; Grochulski, Pawel; Tanaka, Takuji (2024). Structural basis for the allosteric behaviour and substrate specificity of Lactococcus lactis Prolidase. Biochimica et Biophysica Acta - Proteins and Proteomics 1872(3) , 141000. 10.1016/j.bbapap.2024.141000. CMCF-BM, CMCF-ID Health
Walker, Morgan E.; Zhu, Wei; Peterson, Janine H.; Wang, Hao; Patteson, Jon et al. (2025). Antibacterial macrocyclic peptides reveal a distinct mode of BamA inhibition. Nature Communications 16(1) . 10.1038/s41467-025-58086-w. [PDB: 9cs0, 9cs1] CMCF-ID Health
Vu, Binh T.; Dominique, Romyr; Fahr, Bruce J.; Li, Hongju H.; Fry, David C. et al. (2024). Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Medicinal Chemistry Letters . 10.1021/acsmedchemlett.4c00379. [PDB: 9br4] CMCF-ID Health
Vallée, Frédéric; Casás-Selves, Matias; Bubenik, Monica; Duplessis, Martin; Sow, Boubacar et al. (2025). Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor. Journal of Medicinal Chemistry . 10.1021/acs.jmedchem.5c00529. [PDB: 9o63] CMCF-ID Health